Concurrent chemoradiotherapy combined with nimotuzumab in stage III–IVa nasopharyngeal carcinoma: a retrospective analysis

Purpose The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa nasopharyngeal carcinoma (NPC). Methods Patients with stage III–IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and De...

Full description

Saved in:
Bibliographic Details
Published inJournal of cancer research and clinical oncology Vol. 149; no. 6; pp. 2327 - 2344
Main Authors Cai, Zhuochen, Chen, Dongni, Qiu, Wenze, Liang, Chixiong, Huang, Yingying, Zhou, Jiayu, Zhan, Zejiang, Xiang, Yanqun, Guo, Xiang, Lv, Xing
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2023
Springer Nature B.V
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer Research
carcinoma
Chemoradiotherapy
Chemoradiotherapy - adverse effects
Chemotherapy
clinical trials
Hematology
Humans
Immunotherapy
Induction Chemotherapy
Internal Medicine
Medical prognosis
Medicine
Medicine & Public Health
Metastases
Monoclonal antibodies
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - drug therapy
Nasopharyngeal Neoplasms - drug therapy
nomogram
Nomograms
Oncology
Original Article – Clinical Oncology
Original – Clinical Oncology
Patients
prognosis
Prospective Studies
Radiation therapy
regression analysis
Retrospective Studies
Survival
Targeted cancer therapy
therapeutics
Throat cancer
Toxicity
Nasopharyngeal carcinoma
Survival
Concurrent chemoradiotherapy
Nimotuzumab
Prediction model
Online AccessGet full text

Cover

Abstract Purpose The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa nasopharyngeal carcinoma (NPC). Methods Patients with stage III–IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and December 2017. We compared patients’ overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) between different therapeutic regimens. Propensity score matching (PSM) was applied to reduce the selection bias. Nomogram models were developed to predict the survival of CCRT with or without NTZ. Results Four hundred and twenty-six patients were included after PSM, with 213 patients in each regimen. Compared with NPC patients receiving CCRT alone, patients who received NTZ plus CCRT treatment had significantly better OS (5 year OS, 76.1 vs. 72.3%, P  = 0.004), PFS (5 year PFS, 73.2 vs. 69.0%, P  = 0.002), and LRFS (5 year LRFS, 73.2 vs. 69.0%, P  = 0.028). A multivariate Cox regression analysis demonstrated that, compared with receiving CCRT alone, NTZ plus CCRT was an independently positive factor for OS, PFS, and LRFS. No significant difference was observed in the major toxicities between the two treatments (all P  > 0.05). In addition, the nomogram presented good accuracy for predicting the prognosis of NPC patients. Conclusion CCRT combined with NTZ presented favorable clinical outcomes for stage III–IVa NPC patients with good tolerance and similar toxicity compared to CCRT alone. A prospective, randomized clinical trial is essential to validate the current findings.
AbstractList PURPOSE: The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa nasopharyngeal carcinoma (NPC). METHODS: Patients with stage III–IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and December 2017. We compared patients’ overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) between different therapeutic regimens. Propensity score matching (PSM) was applied to reduce the selection bias. Nomogram models were developed to predict the survival of CCRT with or without NTZ. RESULTS: Four hundred and twenty-six patients were included after PSM, with 213 patients in each regimen. Compared with NPC patients receiving CCRT alone, patients who received NTZ plus CCRT treatment had significantly better OS (5 year OS, 76.1 vs. 72.3%, P = 0.004), PFS (5 year PFS, 73.2 vs. 69.0%, P = 0.002), and LRFS (5 year LRFS, 73.2 vs. 69.0%, P = 0.028). A multivariate Cox regression analysis demonstrated that, compared with receiving CCRT alone, NTZ plus CCRT was an independently positive factor for OS, PFS, and LRFS. No significant difference was observed in the major toxicities between the two treatments (all P > 0.05). In addition, the nomogram presented good accuracy for predicting the prognosis of NPC patients. CONCLUSION: CCRT combined with NTZ presented favorable clinical outcomes for stage III–IVa NPC patients with good tolerance and similar toxicity compared to CCRT alone. A prospective, randomized clinical trial is essential to validate the current findings.
PurposeThe efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa nasopharyngeal carcinoma (NPC). MethodsPatients with stage III–IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and December 2017. We compared patients’ overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) between different therapeutic regimens. Propensity score matching (PSM) was applied to reduce the selection bias. Nomogram models were developed to predict the survival of CCRT with or without NTZ.ResultsFour hundred and twenty-six patients were included after PSM, with 213 patients in each regimen. Compared with NPC patients receiving CCRT alone, patients who received NTZ plus CCRT treatment had significantly better OS (5 year OS, 76.1 vs. 72.3%, P = 0.004), PFS (5 year PFS, 73.2 vs. 69.0%, P = 0.002), and LRFS (5 year LRFS, 73.2 vs. 69.0%, P = 0.028). A multivariate Cox regression analysis demonstrated that, compared with receiving CCRT alone, NTZ plus CCRT was an independently positive factor for OS, PFS, and LRFS. No significant difference was observed in the major toxicities between the two treatments (all P > 0.05). In addition, the nomogram presented good accuracy for predicting the prognosis of NPC patients. ConclusionCCRT combined with NTZ presented favorable clinical outcomes for stage III–IVa NPC patients with good tolerance and similar toxicity compared to CCRT alone. A prospective, randomized clinical trial is essential to validate the current findings.
The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III-IVa nasopharyngeal carcinoma (NPC).PURPOSEThe efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III-IVa nasopharyngeal carcinoma (NPC).Patients with stage III-IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and December 2017. We compared patients' overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) between different therapeutic regimens. Propensity score matching (PSM) was applied to reduce the selection bias. Nomogram models were developed to predict the survival of CCRT with or without NTZ.METHODSPatients with stage III-IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and December 2017. We compared patients' overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) between different therapeutic regimens. Propensity score matching (PSM) was applied to reduce the selection bias. Nomogram models were developed to predict the survival of CCRT with or without NTZ.Four hundred and twenty-six patients were included after PSM, with 213 patients in each regimen. Compared with NPC patients receiving CCRT alone, patients who received NTZ plus CCRT treatment had significantly better OS (5 year OS, 76.1 vs. 72.3%, P = 0.004), PFS (5 year PFS, 73.2 vs. 69.0%, P = 0.002), and LRFS (5 year LRFS, 73.2 vs. 69.0%, P = 0.028). A multivariate Cox regression analysis demonstrated that, compared with receiving CCRT alone, NTZ plus CCRT was an independently positive factor for OS, PFS, and LRFS. No significant difference was observed in the major toxicities between the two treatments (all P > 0.05). In addition, the nomogram presented good accuracy for predicting the prognosis of NPC patients.RESULTSFour hundred and twenty-six patients were included after PSM, with 213 patients in each regimen. Compared with NPC patients receiving CCRT alone, patients who received NTZ plus CCRT treatment had significantly better OS (5 year OS, 76.1 vs. 72.3%, P = 0.004), PFS (5 year PFS, 73.2 vs. 69.0%, P = 0.002), and LRFS (5 year LRFS, 73.2 vs. 69.0%, P = 0.028). A multivariate Cox regression analysis demonstrated that, compared with receiving CCRT alone, NTZ plus CCRT was an independently positive factor for OS, PFS, and LRFS. No significant difference was observed in the major toxicities between the two treatments (all P > 0.05). In addition, the nomogram presented good accuracy for predicting the prognosis of NPC patients.CCRT combined with NTZ presented favorable clinical outcomes for stage III-IVa NPC patients with good tolerance and similar toxicity compared to CCRT alone. A prospective, randomized clinical trial is essential to validate the current findings.CONCLUSIONCCRT combined with NTZ presented favorable clinical outcomes for stage III-IVa NPC patients with good tolerance and similar toxicity compared to CCRT alone. A prospective, randomized clinical trial is essential to validate the current findings.
The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III-IVa nasopharyngeal carcinoma (NPC). Patients with stage III-IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and December 2017. We compared patients' overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) between different therapeutic regimens. Propensity score matching (PSM) was applied to reduce the selection bias. Nomogram models were developed to predict the survival of CCRT with or without NTZ. Four hundred and twenty-six patients were included after PSM, with 213 patients in each regimen. Compared with NPC patients receiving CCRT alone, patients who received NTZ plus CCRT treatment had significantly better OS (5 year OS, 76.1 vs. 72.3%, P = 0.004), PFS (5 year PFS, 73.2 vs. 69.0%, P = 0.002), and LRFS (5 year LRFS, 73.2 vs. 69.0%, P = 0.028). A multivariate Cox regression analysis demonstrated that, compared with receiving CCRT alone, NTZ plus CCRT was an independently positive factor for OS, PFS, and LRFS. No significant difference was observed in the major toxicities between the two treatments (all P > 0.05). In addition, the nomogram presented good accuracy for predicting the prognosis of NPC patients. CCRT combined with NTZ presented favorable clinical outcomes for stage III-IVa NPC patients with good tolerance and similar toxicity compared to CCRT alone. A prospective, randomized clinical trial is essential to validate the current findings.
Purpose The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa nasopharyngeal carcinoma (NPC). Methods Patients with stage III–IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and December 2017. We compared patients’ overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) between different therapeutic regimens. Propensity score matching (PSM) was applied to reduce the selection bias. Nomogram models were developed to predict the survival of CCRT with or without NTZ. Results Four hundred and twenty-six patients were included after PSM, with 213 patients in each regimen. Compared with NPC patients receiving CCRT alone, patients who received NTZ plus CCRT treatment had significantly better OS (5 year OS, 76.1 vs. 72.3%, P  = 0.004), PFS (5 year PFS, 73.2 vs. 69.0%, P  = 0.002), and LRFS (5 year LRFS, 73.2 vs. 69.0%, P  = 0.028). A multivariate Cox regression analysis demonstrated that, compared with receiving CCRT alone, NTZ plus CCRT was an independently positive factor for OS, PFS, and LRFS. No significant difference was observed in the major toxicities between the two treatments (all P  > 0.05). In addition, the nomogram presented good accuracy for predicting the prognosis of NPC patients. Conclusion CCRT combined with NTZ presented favorable clinical outcomes for stage III–IVa NPC patients with good tolerance and similar toxicity compared to CCRT alone. A prospective, randomized clinical trial is essential to validate the current findings.
Author Lv, Xing
Liang, Chixiong
Qiu, Wenze
Zhou, Jiayu
Zhan, Zejiang
Xiang, Yanqun
Guo, Xiang
Cai, Zhuochen
Chen, Dongni
Huang, Yingying
Author_xml – sequence: 1
  givenname: Zhuochen
  surname: Cai
  fullname: Cai, Zhuochen
  organization: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center
– sequence: 2
  givenname: Dongni
  surname: Chen
  fullname: Chen, Dongni
  organization: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University
– sequence: 3
  givenname: Wenze
  surname: Qiu
  fullname: Qiu, Wenze
  organization: Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University
– sequence: 4
  givenname: Chixiong
  surname: Liang
  fullname: Liang, Chixiong
  organization: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center
– sequence: 5
  givenname: Yingying
  surname: Huang
  fullname: Huang, Yingying
  organization: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center
– sequence: 6
  givenname: Jiayu
  surname: Zhou
  fullname: Zhou, Jiayu
  organization: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center
– sequence: 7
  givenname: Zejiang
  surname: Zhan
  fullname: Zhan, Zejiang
  organization: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center
– sequence: 8
  givenname: Yanqun
  surname: Xiang
  fullname: Xiang, Yanqun
  organization: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center
– sequence: 9
  givenname: Xiang
  surname: Guo
  fullname: Guo, Xiang
  email: guoxiang@sysucc.org.cn
  organization: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center
– sequence: 10
  givenname: Xing
  orcidid: 0000-0003-3125-6853
  surname: Lv
  fullname: Lv, Xing
  email: lvxing@sysucc.org.cn
  organization: Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36289067$$D View this record in MEDLINE/PubMed
BookMark eNqFUs1u1DAYtFAR3RZegAOyxIVLwD9x4nBB1YqfSJW4AFfLcb7duErsxXa6WsSh79A35Enwsi0_PZSDZdmeGc2MvxN05LwDhJ5S8pISUr-KhJScFYTlVXIhiu0DtKD7K8q5OEILQmtaCEarY3QS4wXJZ1GzR-iYV0w2pKoX6PvSOzOHAC5hM8Dkg-6tTwMEvdlh46fOOujx1qYBOzv5NH-bJ91h63BMeg24bdsfV9ftF42djn4z6LBza9AjNjoY6_ykX2ONA6Tg4wZMspeAtdPjLtr4GD1c6THCk5v9FH1-9_bT8kNx_vF9uzw7L4wgMhVSCmAddB0DKpqVkTlS0_UUJFDTc0Y06QxvcvCO1FwKIqiUkjGWm6HcrPgpenPQ3czdBL3JYYMe1SbYKdtVXlv174uzg1r7S0Vp3VRNLbPCixuF4L_OEJOabDQwjtqBn6PipCRlySva_BfKatbkAIzTDH1-B3rh55DLyShJRM0rIVhGPfvb_W_bt5-YAfIAMLnjGGCljE06Wb8PY0dFidrPizrMi8qtqF_zoraZyu5Qb9XvJfEDKWZw_uzwx_Y9rJ8ZmtWT
CitedBy_id crossref_primary_10_1177_17588359251316094
crossref_primary_10_14639_0392_100X_N2827
crossref_primary_10_2147_OTT_S503674
crossref_primary_10_1016_j_intimp_2024_114005
crossref_primary_10_3389_fphar_2024_1366853
crossref_primary_10_1186_s12885_023_11608_5
crossref_primary_10_1186_s12885_024_12731_7
Cites_doi 10.1186/s12885-017-3552-6
10.1016/S1380-2933(97)00065-1
10.18632/oncotarget.8225
10.1111/j.1349-7006.2008.00836.x
10.1002/ijc.10647
10.1002/cncr.20778
10.1016/j.oraloncology.2013.11.008
10.1080/15384047.2018.1491501
10.3892/ol.2017.7186
10.1016/s1470-2045(16)30410-7
10.1200/JCO.2006.06.1218
10.1093/jnci/djv291
10.1002/ijc.30819
10.1158/0008-5472.CAN-08-4518
10.1002/cncr.32179
10.1038/ncpuro0968
10.3727/096504017x15079846743590
10.1016/j.ijrobp.2020.08.045
10.1016/j.oraloncology.2017.02.026
10.1016/j.oraloncology.2015.06.008
10.1016/j.ijrobp.2004.07.702
10.1016/j.biomaterials.2013.07.100
10.1007/s11523-013-0281-x
10.1186/s12885-016-2974-x
10.1200/JCO.2012.41.5984
10.1200/JCO.2012.41.8343
10.1007/s40265-013-0025-3
10.7150/ijbs.24374
10.1186/s12885-019-6156-5
10.18632/oncotarget.13899
10.1016/j.oraloncology.2018.03.002
10.1016/j.ejca.2015.08.006
10.1016/j.radonc.2017.12.002
10.7150/jca.20461
10.1158/1078-0432.CCR-04-0713
10.2217/fon.13.151
10.7150/thno.19710
10.2147/dddt.S215190
10.1002/cncr.29795
10.6004/jnccn.2017.0121
10.1097/00002371-200303000-00006
10.1200/JCO.20
10.1016/s1470-2045(11)70320-5
10.3322/caac.21389
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright Springer Nature B.V. Jun 2023
The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2022
Copyright_xml – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
– notice: Copyright Springer Nature B.V. Jun 2023
– notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
K9.
M0S
M1P
M2O
MBDVC
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
7S9
L.6
5PM
DOI 10.1007/s00432-022-04355-w
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One
ProQuest Central Korea
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA
Research Library Prep
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-1335
EndPage 2344
ExternalDocumentID PMC11796978
36289067
10_1007_s00432_022_04355_w
Genre Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 81872375; 82172863
  funderid: http://dx.doi.org/10.13039/501100001809
– fundername: Natural Science Foundation of Guangdong Province
  grantid: 2021A1515010118
  funderid: http://dx.doi.org/10.13039/501100003453
– fundername: National Natural Science Foundation of China
  grantid: 82172863
– fundername: National Natural Science Foundation of China
  grantid: 81872375
– fundername: Natural Science Foundation of Guangdong Province
  grantid: 2021A1515010118
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
-~X
.55
.86
.GJ
.VR
06C
06D
0R~
0VY
199
1N0
1SB
2.D
203
28-
29K
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3V.
4.4
406
408
409
40D
40E
53G
5QI
5RE
5VS
67Z
6NX
78A
7X7
88E
8AO
8C1
8FI
8FJ
8G5
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AAHNG
AAIAL
AAJKR
AAJSJ
AAKKN
AANXM
AANZL
AARHV
AARTL
AATVU
AAUYE
AAWCG
AAYIU
AAYOK
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABEEZ
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMOR
ABMQK
ABNWP
ABPLI
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACACY
ACBXY
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACUDM
ACULB
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFFNX
AFGXO
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BVXVI
C24
C6C
CAG
CCPQU
COF
CS3
CSCUP
D-I
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GROUPED_DOAJ
GRRUI
GUQSH
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M2O
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
X7M
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
ZXP
~EX
~KM
AAFWJ
AASML
AAYXX
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFHIU
AFPKN
AGQPQ
AHPBZ
AHWEU
AIXLP
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
7TO
7XB
8FK
H94
K9.
MBDVC
PKEHL
PQEST
PQUKI
PRINS
PUEGO
Q9U
RPM
7X8
7S9
L.6
5PM
ID FETCH-LOGICAL-c508t-885e2bebb2e159fc85219bd1e8e1cd320a0bc39432b0738505188822202213cf3
IEDL.DBID 7X7
ISSN 0171-5216
1432-1335
IngestDate Thu Aug 21 18:24:44 EDT 2025
Fri Jul 11 10:30:10 EDT 2025
Sun Aug 24 03:25:32 EDT 2025
Sat Aug 23 14:51:41 EDT 2025
Sun Jul 20 01:30:41 EDT 2025
Thu Apr 24 23:08:08 EDT 2025
Tue Jul 01 01:39:12 EDT 2025
Fri Feb 21 02:43:24 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Nasopharyngeal carcinoma
Survival
Concurrent chemoradiotherapy
Nimotuzumab
Prediction model
Language English
License 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c508t-885e2bebb2e159fc85219bd1e8e1cd320a0bc39432b0738505188822202213cf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ORCID 0000-0003-3125-6853
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/11796978
PMID 36289067
PQID 2805736552
PQPubID 47182
PageCount 18
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11796978
proquest_miscellaneous_3040443619
proquest_miscellaneous_2729521231
proquest_journals_2805736552
pubmed_primary_36289067
crossref_citationtrail_10_1007_s00432_022_04355_w
crossref_primary_10_1007_s00432_022_04355_w
springer_journals_10_1007_s00432_022_04355_w
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-06-01
PublicationDateYYYYMMDD 2023-06-01
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-01
  day: 01
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Journal of cancer research and clinical oncology
PublicationTitleAbbrev J Cancer Res Clin Oncol
PublicationTitleAlternate J Cancer Res Clin Oncol
PublicationYear 2023
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Xu, Liu, Dou, Li, Guan, Zhu (CR36) 2015; 51
Yan, Cao, Wang (CR38) 2017; 14
Dorsey, Agulnik (CR5) 2013; 73
Ying, Wen-Fei, Nian-Yong, Ning, Guo-Qing, Fang-Yun, Yan, Xiao-Zhong, Jin-Gao, Xiao-Dong, Chao-Su, Xiang-Ying, Yuan-Yuan, Wei-Han, Ling, Hao-Yuan, Lei, Yan-Ping, Rui, Ping, Shao-Bo, Guo-Xian, Bao-Min, Xing-Lai, Xiao-Chang, Ling, Chun-Ying, Jian-Yu, Ying, Yu-Ming, Fan, Li, Ling-Long, Meng-Zhong, M J (CR41) 2016; 17
Xue-Song, Yu-Jing, Xiao-Yun, Sai-Lan, Qiu-Yan, Lin-Quan, Hai-Qiang (CR37) 2019; 13
Karakiewicz, Briganti, Chun, Trinh, Perrotte, Ficarra, Cindolo, De La Taille, Tostain, Mulders, Salomon, Zigeuner, Prayer-Galetti, Chautard, Valeri, Lechevallier, Descotes, Lang, Mejean, Patard (CR14) 2007; 25
CR19
Zhi-Gang, Yu, Jiao, Yu-Juan, Wen-Juan, Yan-Fang, Hui (CR45) 2016
CR17
Fangzheng, Quanquan, Chuner, Tongxin, Aizawa, Sakamoto, Yuezhen, Zhenfu, Chen (CR7) 2018; 9
Yizhou, Jun, Yong, Renyan, Kui, Zhenlin, Xuying, Guanghua, Dong, Lehua, Wanyee, Mengchao, Shen (CR42) 2013; 31
CR34
Prenen, Vecchione, Van Cutsem (CR25) 2013; 8
Robert, David, Marisa Dolled (CR27) 2004; 10
Fortunato, Giampaolo (CR8) 2001; 7
CR31
Yuan, Wen-Fei, Xu, Lei, Rui, Ying, Qing, Jun (CR43) 2018; 129
Jian-Yong, Yu, Yu-Hong, Hong-Yi, Hui-Xia, Qiu-Liang, Nian-Ji, Gang, Bin, Li-Fu, Ingemar, Yi-Xin (CR12) 2004; 24
Reddy, Lokesh, Vidyasagar, Shenoy, Babu, Shenoy, Naveen, Joseph, Bonanthaya, Nanjundappa, Loknatha, Prasad, Tanvir Pasha (CR26) 2014; 50
Rui, Yi-Jun, You-Ping, Qi, Yi-Nuan, Ji-Bin, Chao-Feng, Xiong, Tao, Jing-Yu, Meng-Xia, Rou, Rui, Hao-Yuan, Ling, Ka-Jia, Ai-Hua, Ying, Chao-Nan, Jun, Ming-Yuan (CR29) 2017; 7
Mei, Rui, You-Ping, Yi-Nuan, Hao-Jiong, Xiong, Qi, Li, Yi-Jun, Tao, Jing-Yu, Ji-Bin, Hao-Yuan, Ling, Ai-Hua, Ying, Chao-Nan, Jun, Hai-Qiang, Ming-Yuan (CR22) 2018; 80
Wang-Zhong, Shu-Hui, Guo-Ying, Hu, Xiang, Xing, Kui-Yuan, Meng-Yun, Xi, Zg, Chang-Qing, Wei-Xiong, Xiang (CR32) 2021; 109
Ji-Jin, Guan-Qun, Si-Yang, Lu-Lu, Tian-Sheng, Ying-Lin, Wayne, Ying, Wang-Jian, Fan (CR13) 2018; 19
Lin-Quan, Chao-Feng, Jing, Wen-Hui, Qiu-Yan, Lian-Xiong, Xiao-Ping, Yun, Yun-Xiu-Xiu, Dong-Peng, Shi-Hua, Yu-Tuan, Lu, Shan-Shan, Li-Ting, Ling, Yi-Shan, Dong-Hua, Pei-Yu, Hao-Yuan, Yan-Qun, Rui, Ming-Yuan, Yi-Jun, Xing, Lin, Chong, Ka-Jia, Chao-Nan, Xiang, Yi-Xin, Hai-Qiang, Mu-Sheng (CR20) 2015
Yang, Qiu-Yan, Lin-Quan, Li-Ting, Shan-Shan, Ling, Hao-Yuan, Ming-Yuan, Xiang, Ka-Jia, Chao-Nan, Mu-Shen, Jin-Xin, Jian-Yong, Ying, Jing, Shuai, Jun, Chong, Hai-Qiang (CR39) 2017
Rui, Rui, Yi-Jun, Chao-Feng, Ji-Bin, Xiong, Qi, You-Ping, Yi-Nuan, Tao, Jing-Yu, Meng-Xia, Rou, Hao-Yuan, Ling, Ka-Jia, Ai-Hua, Chao-Nan, Ying, Jun, Ming-Yuan (CR28) 2017; 141
Fangzheng, Chuner, Zhiming, Tongxin, Fengqin, Lei, Bin, Fujun, Ming, Weifeng, Zhenfu (CR6) 2018; 26
Li, Li, Qian, Wu, Xie, Wang, Zhang, Liu (CR18) 2016
Lee, Sze, Au, Leung, Leung, Chua, Zee, Law, Teo, Tung, Kwong, Lau (CR16) 2005; 61
Yewale, Baradia, Vhora, Patil, Misra (CR40) 2013; 34
Brigette, Edwin, Anthony (CR1) 2008; 99
Jian-Feng, Fu-Zheng, Qin-Zhou, Le-Yuan, Bo, Jian-Jun, Jia-Hua, Hao-Wen, Xiao-Peng, Guo-Mei, Fen-Ju, Charlie (CR10) 2017; 8
Kattan, Scardino (CR15) 2007; 4
Crombet-Ramos, Rak, Perez, Viloria-Petit (CR3) 2002; 101
CR9
Xia, Jianhua, Wenjie, Xuesong, Xue, Dan (CR35) 2013; 9
Jianpei, Shulin, Songguo, Yijun, Shan, Xia, Chen (CR11) 2018; 14
CR44
Zhi-Qiang, Qi, Ji-Bin, Rui, You-Ping, Rui, Guang-Yuan, Ming-Yuan, Yi-Jun (CR46) 2019
Cristina, Ernest, Kathryn, Josefa, William, Rolando (CR2) 1997; 3
Patil, Noronha, Joshi, Agarwal, Ghosh-Laskar, Budrukkar, Murthy, Gupta, Mahimkar, Juvekar, Arya, Mahajan, Agarwal, Purandare, Rangarajan, Balaji, Chaudhari, Banavali, Kannan, Bhattacharjee, D’cruz, Chaturvedi, Pai, Chaukar, Pantvaidya, Nair, Nair, Deshmukh, Thiagarajan, Mathrudev, Manjrekar, Dhumal, Maske, Bhelekar, Nawale, Chandrasekharan, Pande, Goel, Talreja, Simha, Srinivas, Swami, Vallathol, Dsouza, Shrirangwar, Turkar, Abraham, Thanky, Patel, Pandey, Prabhash (CR24) 2019; 125
Dong-Seok, Yun-Suhk, Seong-Ho, Hyuk-Joon, Yunhee, Susumu, Takeshi, Byung-Joo, Woo-Ho, Yang (CR4) 2012; 30
Mariani, Miceli, Kattan, Brennan, Colecchia, Fiore, Casali, Gronchi (CR21) 2005; 103
Meng-Xia, Jing, Guo-Ping, Jun-Jie, Rou, Rui, Yi-Jun, Ying, Jun, Ming-Huang, Ming-Yuan (CR23) 2015; 51
Talavera, Friemann, Gomez-Puerta, Martinez-Fleites, Garrido, Rabasa, Lopez-Requena, Pupo, Johansen, Sanchez, Krengel, Moreno (CR30) 2009; 69
Wei-Xiong, Hu, Xing, Lin, Chao-Nan, Yan-Fang, Liang-Ru, Wen-Ze, Ya-Hui, Xin-Jun, Guo-Ying, Chong, Yan-Qun, Xiang (CR33) 2017; 67
A Talavera (4355_CR30) 2009; 69
Y Ji-Jin (4355_CR13) 2018; 19
S Jian-Yong (4355_CR12) 2004; 24
4355_CR34
C Fortunato (4355_CR8) 2001; 7
4355_CR17
H Jian-Feng (4355_CR10) 2017; 8
AW Lee (4355_CR16) 2005; 61
4355_CR19
PI Karakiewicz (4355_CR14) 2007; 25
X Wei-Xiong (4355_CR33) 2017; 67
W Fangzheng (4355_CR7) 2018; 9
H Xia (4355_CR35) 2013; 9
W Yizhou (4355_CR42) 2013; 31
4355_CR31
W Fangzheng (4355_CR6) 2018; 26
T Lin-Quan (4355_CR20) 2015
H Yan (4355_CR38) 2017; 14
L Jianpei (4355_CR11) 2018; 14
W Zhi-Qiang (4355_CR46) 2019
VM Patil (4355_CR24) 2019; 125
Z Yuan (4355_CR43) 2018; 129
S Xue-Song (4355_CR37) 2019; 13
H Dong-Seok (4355_CR4) 2012; 30
K Dorsey (4355_CR5) 2013; 73
MW Kattan (4355_CR15) 2007; 4
H Prenen (4355_CR25) 2013; 8
4355_CR9
LC Robert (4355_CR27) 2004; 10
L Yang (4355_CR39) 2017
T Crombet-Ramos (4355_CR3) 2002; 101
L Mariani (4355_CR21) 2005; 103
L Zhi-Gang (4355_CR45) 2016
HM Li (4355_CR18) 2016
BYM Brigette (4355_CR1) 2008; 99
T Xu (4355_CR36) 2015; 51
BKM Reddy (4355_CR26) 2014; 50
Z Meng-Xia (4355_CR23) 2015; 51
Y Rui (4355_CR29) 2017; 7
L Wang-Zhong (4355_CR32) 2021; 109
L Mei (4355_CR22) 2018; 80
S Ying (4355_CR41) 2016; 17
4355_CR44
Y Rui (4355_CR28) 2017; 141
C Yewale (4355_CR40) 2013; 34
M Cristina (4355_CR2) 1997; 3
References_xml – year: 2017
  ident: CR39
  article-title: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study
  publication-title: BMC Cancer
  doi: 10.1186/s12885-017-3552-6
– volume: 3
  start-page: 71
  year: 1997
  end-page: 81
  ident: CR2
  article-title: Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity
  publication-title: Immunotechnology
  doi: 10.1016/S1380-2933(97)00065-1
– year: 2016
  ident: CR45
  article-title: Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8225
– volume: 99
  start-page: 1311
  year: 2008
  end-page: 1318
  ident: CR1
  article-title: Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2008.00836.x
– volume: 101
  start-page: 567
  year: 2002
  end-page: 575
  ident: CR3
  article-title: Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody
  publication-title: Int J Cancer
  doi: 10.1002/ijc.10647
– volume: 103
  start-page: 402
  year: 2005
  end-page: 408
  ident: CR21
  article-title: Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system
  publication-title: Cancer
  doi: 10.1002/cncr.20778
– volume: 50
  start-page: 498
  year: 2014
  end-page: 505
  ident: CR26
  article-title: Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2013.11.008
– volume: 19
  start-page: 1102
  year: 2018
  end-page: 1107
  ident: CR13
  article-title: Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2018.1491501
– volume: 14
  start-page: 7773
  year: 2017
  end-page: 7776
  ident: CR38
  article-title: Application of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma
  publication-title: Oncol Lett
  doi: 10.3892/ol.2017.7186
– volume: 17
  start-page: 1509
  year: 2016
  end-page: 1520
  ident: CR41
  article-title: Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(16)30410-7
– volume: 25
  start-page: 1316
  year: 2007
  end-page: 1322
  ident: CR14
  article-title: Multi-institutional validation of a new renal cancer-specific survival nomogram
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.06.1218
– year: 2015
  ident: CR20
  article-title: Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djv291
– volume: 141
  start-page: 1265
  year: 2017
  end-page: 1276
  ident: CR28
  article-title: Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II–IVb nasopharyngeal carcinoma
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30819
– volume: 69
  start-page: 5851
  year: 2009
  end-page: 5859
  ident: CR30
  article-title: Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-4518
– volume: 125
  start-page: 3184
  year: 2019
  end-page: 3197
  ident: CR24
  article-title: A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer
  publication-title: Cancer
  doi: 10.1002/cncr.32179
– volume: 4
  start-page: 638
  year: 2007
  end-page: 639
  ident: CR15
  article-title: Evidence for the usefulness of nomograms
  publication-title: Nat Clin Pract Urol
  doi: 10.1038/ncpuro0968
– volume: 26
  start-page: 277
  year: 2018
  end-page: 287
  ident: CR6
  article-title: Long-term use of nimotuzumab in combination with intensity-modulated radiotherapy and chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma: experience of a single institution
  publication-title: Oncol Res Featuring Preclin Clin Cancer Ther
  doi: 10.3727/096504017x15079846743590
– volume: 109
  start-page: 120
  year: 2021
  end-page: 130
  ident: CR32
  article-title: Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2020.08.045
– volume: 67
  start-page: 167
  year: 2017
  end-page: 174
  ident: CR33
  article-title: Combining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a propensity score analysis
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2017.02.026
– volume: 51
  start-page: 875
  year: 2015
  end-page: 879
  ident: CR36
  article-title: Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2015.06.008
– volume: 61
  start-page: 1107
  year: 2005
  end-page: 1116
  ident: CR16
  article-title: Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2004.07.702
– volume: 34
  start-page: 8690
  year: 2013
  end-page: 8707
  ident: CR40
  article-title: Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.07.100
– volume: 8
  start-page: 83
  year: 2013
  end-page: 96
  ident: CR25
  article-title: Role of targeted agents in metastatic colorectal cancer
  publication-title: Target Oncol
  doi: 10.1007/s11523-013-0281-x
– year: 2016
  ident: CR18
  article-title: A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2974-x
– volume: 31
  start-page: 1188
  year: 2013
  end-page: 1195
  ident: CR42
  article-title: Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.41.5984
– ident: CR19
– ident: CR44
– volume: 24
  start-page: 4059
  year: 2004
  end-page: 4066
  ident: CR12
  article-title: Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma
  publication-title: Anticancer Res
– volume: 7
  start-page: 2958
  year: 2001
  end-page: 2970
  ident: CR8
  article-title: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor
  publication-title: Clin Cancer Res
– volume: 30
  start-page: 3834
  year: 2012
  end-page: 3840
  ident: CR4
  article-title: Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.41.8343
– volume: 73
  start-page: 315
  year: 2013
  end-page: 325
  ident: CR5
  article-title: Promising new molecular targeted therapies in head and neck cancer
  publication-title: Drugs
  doi: 10.1007/s40265-013-0025-3
– volume: 14
  start-page: 549
  year: 2018
  end-page: 556
  ident: CR11
  article-title: Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics
  publication-title: Int J of Biol Sci
  doi: 10.7150/ijbs.24374
– year: 2019
  ident: CR46
  article-title: The long-term survival of patients with III–IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-6156-5
– ident: CR17
– ident: CR31
– ident: CR9
– volume: 8
  start-page: 2754
  year: 2017
  end-page: 2465
  ident: CR10
  article-title: Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13899
– volume: 80
  start-page: 1
  year: 2018
  end-page: 8
  ident: CR22
  article-title: Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2018.03.002
– volume: 51
  start-page: 2587
  year: 2015
  end-page: 2595
  ident: CR23
  article-title: Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.08.006
– ident: CR34
– volume: 129
  start-page: 18
  year: 2018
  end-page: 22
  ident: CR43
  article-title: Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: analysis of a multicenter, phase III randomized trial
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2017.12.002
– volume: 9
  start-page: 594
  year: 2018
  end-page: 603
  ident: CR7
  article-title: Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis
  publication-title: J Cancer
  doi: 10.7150/jca.20461
– volume: 10
  start-page: 7252
  year: 2004
  end-page: 7259
  ident: CR27
  article-title: X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0713
– volume: 9
  start-page: 1459
  year: 2013
  end-page: 1467
  ident: CR35
  article-title: Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results
  publication-title: Future Oncol
  doi: 10.2217/fon.13.151
– volume: 7
  start-page: 2314
  year: 2017
  end-page: 2324
  ident: CR29
  article-title: Concurrent chemoradiotherapy with or without anti-EGFR-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up
  publication-title: Theranostics
  doi: 10.7150/thno.19710
– volume: 13
  start-page: 3207
  year: 2019
  end-page: 3216
  ident: CR37
  article-title: Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study
  publication-title: Drug Des Dev Ther
  doi: 10.2147/dddt.S215190
– ident: 4355_CR9
  doi: 10.1002/cncr.29795
– volume: 109
  start-page: 120
  year: 2021
  ident: 4355_CR32
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2020.08.045
– volume: 30
  start-page: 3834
  year: 2012
  ident: 4355_CR4
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.41.8343
– ident: 4355_CR19
  doi: 10.6004/jnccn.2017.0121
– volume: 61
  start-page: 1107
  year: 2005
  ident: 4355_CR16
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2004.07.702
– volume: 25
  start-page: 1316
  year: 2007
  ident: 4355_CR14
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.06.1218
– year: 2017
  ident: 4355_CR39
  publication-title: BMC Cancer
  doi: 10.1186/s12885-017-3552-6
– volume: 99
  start-page: 1311
  year: 2008
  ident: 4355_CR1
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2008.00836.x
– volume: 125
  start-page: 3184
  year: 2019
  ident: 4355_CR24
  publication-title: Cancer
  doi: 10.1002/cncr.32179
– volume: 50
  start-page: 498
  year: 2014
  ident: 4355_CR26
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2013.11.008
– volume: 141
  start-page: 1265
  year: 2017
  ident: 4355_CR28
  publication-title: Int J Cancer
  doi: 10.1002/ijc.30819
– volume: 80
  start-page: 1
  year: 2018
  ident: 4355_CR22
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2018.03.002
– volume: 69
  start-page: 5851
  year: 2009
  ident: 4355_CR30
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-4518
– volume: 101
  start-page: 567
  year: 2002
  ident: 4355_CR3
  publication-title: Int J Cancer
  doi: 10.1002/ijc.10647
– volume: 7
  start-page: 2314
  year: 2017
  ident: 4355_CR29
  publication-title: Theranostics
  doi: 10.7150/thno.19710
– volume: 17
  start-page: 1509
  year: 2016
  ident: 4355_CR41
  publication-title: Lancet Oncol
  doi: 10.1016/s1470-2045(16)30410-7
– volume: 73
  start-page: 315
  year: 2013
  ident: 4355_CR5
  publication-title: Drugs
  doi: 10.1007/s40265-013-0025-3
– year: 2016
  ident: 4355_CR18
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2974-x
– volume: 103
  start-page: 402
  year: 2005
  ident: 4355_CR21
  publication-title: Cancer
  doi: 10.1002/cncr.20778
– volume: 51
  start-page: 875
  year: 2015
  ident: 4355_CR36
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2015.06.008
– volume: 13
  start-page: 3207
  year: 2019
  ident: 4355_CR37
  publication-title: Drug Des Dev Ther
  doi: 10.2147/dddt.S215190
– volume: 129
  start-page: 18
  year: 2018
  ident: 4355_CR43
  publication-title: Radiother Oncol
  doi: 10.1016/j.radonc.2017.12.002
– year: 2019
  ident: 4355_CR46
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-6156-5
– volume: 7
  start-page: 2958
  year: 2001
  ident: 4355_CR8
  publication-title: Clin Cancer Res
– volume: 24
  start-page: 4059
  year: 2004
  ident: 4355_CR12
  publication-title: Anticancer Res
– volume: 8
  start-page: 83
  year: 2013
  ident: 4355_CR25
  publication-title: Target Oncol
  doi: 10.1007/s11523-013-0281-x
– ident: 4355_CR31
  doi: 10.1097/00002371-200303000-00006
– volume: 34
  start-page: 8690
  year: 2013
  ident: 4355_CR40
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.07.100
– volume: 31
  start-page: 1188
  year: 2013
  ident: 4355_CR42
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.41.5984
– volume: 10
  start-page: 7252
  year: 2004
  ident: 4355_CR27
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-04-0713
– year: 2015
  ident: 4355_CR20
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djv291
– volume: 67
  start-page: 167
  year: 2017
  ident: 4355_CR33
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2017.02.026
– volume: 26
  start-page: 277
  year: 2018
  ident: 4355_CR6
  publication-title: Oncol Res Featuring Preclin Clin Cancer Ther
  doi: 10.3727/096504017x15079846743590
– volume: 9
  start-page: 594
  year: 2018
  ident: 4355_CR7
  publication-title: J Cancer
  doi: 10.7150/jca.20461
– volume: 8
  start-page: 2754
  year: 2017
  ident: 4355_CR10
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.13899
– volume: 14
  start-page: 549
  year: 2018
  ident: 4355_CR11
  publication-title: Int J of Biol Sci
  doi: 10.7150/ijbs.24374
– volume: 51
  start-page: 2587
  year: 2015
  ident: 4355_CR23
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2015.08.006
– volume: 3
  start-page: 71
  year: 1997
  ident: 4355_CR2
  publication-title: Immunotechnology
  doi: 10.1016/S1380-2933(97)00065-1
– ident: 4355_CR44
  doi: 10.1200/JCO.20
– volume: 14
  start-page: 7773
  year: 2017
  ident: 4355_CR38
  publication-title: Oncol Lett
  doi: 10.3892/ol.2017.7186
– ident: 4355_CR17
  doi: 10.1016/s1470-2045(11)70320-5
– volume: 9
  start-page: 1459
  year: 2013
  ident: 4355_CR35
  publication-title: Future Oncol
  doi: 10.2217/fon.13.151
– year: 2016
  ident: 4355_CR45
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.8225
– volume: 4
  start-page: 638
  year: 2007
  ident: 4355_CR15
  publication-title: Nat Clin Pract Urol
  doi: 10.1038/ncpuro0968
– volume: 19
  start-page: 1102
  year: 2018
  ident: 4355_CR13
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2018.1491501
– ident: 4355_CR34
  doi: 10.3322/caac.21389
SSID ssj0017572
Score 2.4249475
Snippet Purpose The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa...
The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III-IVa nasopharyngeal...
PurposeThe efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa...
PURPOSE: The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2327
SubjectTerms Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer Research
carcinoma
Chemoradiotherapy
Chemoradiotherapy - adverse effects
Chemotherapy
clinical trials
Hematology
Humans
Immunotherapy
Induction Chemotherapy
Internal Medicine
Medical prognosis
Medicine
Medicine & Public Health
Metastases
Monoclonal antibodies
Nasopharyngeal carcinoma
Nasopharyngeal Carcinoma - drug therapy
Nasopharyngeal Neoplasms - drug therapy
nomogram
Nomograms
Oncology
Original Article – Clinical Oncology
Original – Clinical Oncology
Patients
prognosis
Prospective Studies
Radiation therapy
regression analysis
Retrospective Studies
Survival
Targeted cancer therapy
therapeutics
Throat cancer
Toxicity
SummonAdditionalLinks – databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSIgLKu-0BRmJG1hK4sc6vVUVVRepnFjUW2Q7E1iJdartrqoiDv0P_EN-SceOE7SUInGL5Iljz_gxk5n5hpA3oip126qSKbR_mNDAmeVtw2ShwLqigjymR598VMcz8eFUnqaksPMh2n1wScaTekx2i-hxLESf44OU7OIuuSeD7Y6reFYejL6DiYwlmwIQDJpZhUqpMn_vY_M6uqFj3gyV_MNfGq-ho23yMOmP9KAX-CNyB_xjcv8kecifkB-HnXc95hJFeSxQws08ZVldUpwpWsLQ0PD7lfogp_X39cJYOvcU9cQvQKfT6a-rn9PPhnoTShyY5SWOAz_pQtUh3y3MPjV0CatlN2RpUpOQTZ6S2dH7T4fHLFVYYA4VsxXTWkJpwdoSUK1pnUZ-VbYpQEPhGl7mJreOV8gzmwfYmzzAtwWVAjlYcNfyZ2TLdx5eEMpNC6LVMJFCCeOaatLkE6NVY6UoXA4ZKQZG1y7Bj4cqGN_qETg5CqfGrusonPoiI2_Hd8568I1_Uu8N8qvTRjyvSx0QH5WUZUZej824hYJfxHjo1kiDBkZMYS5up-F42AnB0dzMyPN-SYxDQh1AV3jrZ0RvLJaRIEB4b7b4-dcI5R0A-RQa8hl5N6yr32O_fao7_0e-Sx6gxHgf4bZHtlbLNbxEXWplX8Wtcw0XJBjB
  priority: 102
  providerName: Springer Nature
Title Concurrent chemoradiotherapy combined with nimotuzumab in stage III–IVa nasopharyngeal carcinoma: a retrospective analysis
URI https://link.springer.com/article/10.1007/s00432-022-04355-w
https://www.ncbi.nlm.nih.gov/pubmed/36289067
https://www.proquest.com/docview/2805736552
https://www.proquest.com/docview/2729521231
https://www.proquest.com/docview/3040443619
https://pubmed.ncbi.nlm.nih.gov/PMC11796978
Volume 149
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1fb9MwELdgkxAvE__JGJOReAOLJE5ShxfUVi0raBVCFJWnyHYcqESd0bWahnjgO_AN-STcOU6mMm0vSSRfEttn--7su98R8jzJY1FVWcwysH9YIgxnilclS6PMKB3lJnTh0cfT7GiWvJunc7_hdurdKts10S3UZa1xj_xVLBC6L0vT-M3JD4ZZo_B01afQuEl2EboMXbp6887gAsnokjchJAwYXFHmg2Zc6JzDomPoyw4PacrOtgXTJW3zstPkfyenTiCN75A9r0nSfsP6u-SGsffIrWN_Vn6f_BrWVjfoSxQ4swRelwsfb3VOodFgE5uS4kYstcixzc_NUiq6sBQ0xq-GTiaTv7__TD5LaiUmO5Crc6gH_FJj_iFbL-VrKunKrFd1G69Jpcc4eUBm49Gn4RHzuRaYBhVtzYRITayMUrEBBafSAvorV2VkhIl0yeNQhkrzHPpMhQiAEyKQGyoX0IMR1xV_SHZsbc1jQrmsTFIJ00uTLJG6zHtl2JMiK1WaRDo0AYnaji60ByLHfBjfiw5C2TGngE8XjjnFWUBedO-cNDAc11IftPwr_JQ8LS4GUECedcUwmfCERFpTb4AGTA0XzBxdTcNh2UsSDoZnQB41Q6KrEmgDIgf5HxCxNVg6AgTz3i6xi28O1Buh-TIw6QPysh1XF3W_uqn71zf1CbkNHOKNb9sB2VmvNuYpaFFrdeimClzFMDoku_3xYDDF-9sv70dwH4ymHz5C6Szu_wMTcCHM
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VrQRcEP8EChgJThA1juOsg4QQlFYb2l0h1KLegu04sBLrlO2uVos48A68Bw_FkzDOX7VU7a23SHYSx_PZM5PxfAPwNEpCURRx6Mfo__iRMMxXrMh9TmOjNE1MUKVHD0fx4CB6f8gP1-BPmwvjjlW2e2K1Ueeldv_IN0PhqPtizsPXR999VzXKRVfbEho1LHbNcoEu2_Gr9B3K91kY7mzvbw38pqqAr9EYmflCcBMqo1RoUJUXWqACS1ROjTBU5ywMZKA0SyIWqsBRvQSOssypUdR2lOmC4XMvwXrE0JXpwfrb7dGHj13cos-rclGOhAZdPBo3aTpVsl7Ffue70_N4wbm_WFWFp-zb08c0_4vVVipw5zpca2xX8qYG2w1YM_YmXB420flb8HOrtLrmeyKIhQmiKx83GV5LgtOMXrjJifv1S6zDyPzHfCIVGVuCNuoXQ9I0_fvrd_pJEitdeQU5XeI48JXaVTyy5US-JJJMzWxathmiRDasKrfh4ELkcAd6trTmHhAmCxMVwvR5FEdS50k_D_pSxLniEdWB8YC2E53phvrcVeD4lnWkzZVwMnx0VgknW3jwvLvnqCb-OLf3Riu_rNkEjrMTyHrwpGvG5etiMtKaco590Lmp0qfp2X0YbrQR4o0mHtytIdENCe0PkaDF4YFYAUvXwdGHr7bY8deKRtyRAcZJX3jwosXVydjP_tT753_qY7gy2B_uZXvpaPcBXEVpsfpk3Qb0ZtO5eYg23Ew9ahYOgc8XvVb_AQp6V8U
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwEB6VIlVcEC0_DRRqJDhB1MSOEwcJIdSyaiitOFC0t2A7DqzEJmW7q9UiDrxD34bH4UkYOz_VUrW33iLFSZzMN56ZeOYbgGdRSkVZxtSPMf7xI2GYr1hZ-DyMjdJhagJXHn14FO8fR--HfLgCf7paGJtW2a2JbqEuam3_ke9QYan7Ys7pTtmmRXzcG7w5-eHbDlJ2p7Vrp9FA5MAs5hi-nb7O9lDWzykdvPu0u--3HQZ8jY7J1BeCG6qMUtSgWS-1QGOWqiI0woS6YDSQgdIsjRhVgaV9CSx9mTWpaPlCpkuG970BNxPGQ6tjybAP9tAqu8ZRlo4Gg70wbgt2XNme48HzbR49HnDuz5eN4gVP92LC5n-7ts4YDu7A7daLJW8b2K3Diqk2YO2w3ae_C79260o3zE8EUTFGnBWjttZrQfCDYzxuCmJ_ApPKomX2czaWiowqgt7qV0OyLPv7-yz7LEklbaMFOVngPPCR2vY-quqxfEUkmZjppO5qRYls-VXuwfG1SOE-rFZ1ZTaBMFmaqBQm4VEcSV2kSREkUsSF4lGoA-NB2H3oXLck6LYXx_e8p292wsnx1rkTTj734EV_zUlDAXLl6K1Ofnm7HJzm5-D14Gl_GhXZ7s7IytQzHINhjiukDi8fw3DJjSKGQa8HDxpI9FNCT0Sk6Ht4IJbA0g-wROLLZ6rRN0cobmkB4zQRHrzscHU-98tf9eHVr7oNa6ih-Yfs6OAR3EJhsSbFbgtWp5OZeYzO3FQ9cVpD4Mt1q-k_RRValQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Concurrent+chemoradiotherapy+combined+with+nimotuzumab+in+stage+III-IVa+nasopharyngeal+carcinoma%3A+a+retrospective+analysis&rft.jtitle=Journal+of+cancer+research+and+clinical+oncology&rft.au=Cai%2C+Zhuochen&rft.au=Chen%2C+Dongni&rft.au=Qiu%2C+Wenze&rft.au=Liang%2C+Chixiong&rft.date=2023-06-01&rft.issn=1432-1335&rft.eissn=1432-1335&rft.volume=149&rft.issue=6&rft.spage=2327&rft_id=info:doi/10.1007%2Fs00432-022-04355-w&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0171-5216&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0171-5216&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0171-5216&client=summon